Alain Munoz joins Hybrigenics board
This article was originally published in Scrip
Executive Summary
Hybrigenics, a Paris-based biopharma developing treatments for proliferative diseases and specialised protein interactions, has appointed Dr Alain Munoz to its board as a non-executive independent director replacing Dr Bernhard Ehmer, president of ImClone Systems. Dr Munoz has over 20 years' experience at senior management level with companies such as Sanofi and Fournier.